Product Description
Calcium folinate is a tetrahydrofolic acid. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Calcium-folinate)
Mechanisms of Action: TS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Denmark | Dominican Republic | Egypt | France | Germany | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Japan | Korea | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | New Zealand | Norway | Pakistan | Philippines | Portugal | Russia | Saudi Arabia | Serbia | South Africa | Spain | Sri Lanka | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: ImmunityBio
Company Location: Western America
Company CEO: Richard Adcock
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Netherlands, Norway, Poland, Portugal, Puerto Rico, Slovakia, South Korea, Spain, Switzerland, Taiwan, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 55
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Lymphoid Leukemia|Adenocarcinoma|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Pancreatic Cancer|Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase 2: Biliary Tract Cancer|Liver Cancer|Neuroendocrine Carcinoma|Pancreatic Ductal Carcinoma|Squamous Cell Carcinoma
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04469556 |
PASS-01 | P2 |
Active, not recruiting |
Pancreatic Ductal Carcinoma|Pancreatic Cancer|Adenocarcinoma |
2025-01-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT03837977 |
NET02 | P2 |
Completed |
Neuroendocrine Carcinoma |
2024-11-26 |
57% |
2025-01-03 |
|
2018-000708-40 |
ARION | P2 |
Active, not recruiting |
Esophageal Cancer|Adenocarcinoma|Squamous Cell Carcinoma |
2024-06-05 |
2022-03-13 |
Treatments |
|
NCT03020030 |
NCT03020030 | P3 |
Active, not recruiting |
Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2026-11-30 |
50% |
2025-01-04 |
|
NCT05253651 |
MOUNTAINEER-03 | P3 |
Recruiting |
Colorectal Cancer |
2026-04-03 |
42% |
2025-02-22 |
|
NCT04375605 |
RACE-trial | P3 |
Active, not recruiting |
Gastrointestinal Cancer|Esophageal Cancer|Adenocarcinoma |
2025-12-01 |
2023-12-27 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
ACTRN12617001268336 |
SYS-CAPLIOX | P2 |
Recruiting |
Colorectal Cancer|Liver Cancer |
2023-05-01 |
2026-01-11 |
Treatments |
|
ACTRN12619001533189 |
FP101A | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2023-03-20 |
2024-08-29 |
Treatments |
|
NCT04005339 |
NAPOLI-2 | P2 |
Recruiting |
Biliary Tract Cancer |
2025-12-30 |
12% |
2025-07-02 |
Primary Completion Date|Primary Endpoints|Treatments |
NCT07314385 |
202410052MIPA | P1 |
Not yet recruiting |
Adenocarcinoma|Pancreatic Cancer |
2027-12-31 |
50% |
2026-01-03 |
Primary Endpoints|Treatments |
NCT06792695 |
CANTOR | P2 |
Recruiting |
Colorectal Cancer |
2027-05-31 |
12% |
2025-10-08 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT07257575 |
SPACE-neo | P2 |
Active, not recruiting |
Gastrointestinal Cancer |
2027-01-31 |
12% |
2025-12-03 |
Primary Endpoints|Treatments |
NCT04495088 |
ACO/ARO/AIO-18.2 | P3 |
Recruiting |
Colorectal Cancer |
2030-08-01 |
2020-11-13 |
Primary Endpoints|Start Date |
|
NCT06205485 |
NEO-RT | P3 |
Recruiting |
Colorectal Cancer |
2030-01-30 |
2024-08-14 |
Primary Endpoints|Start Date |
|
2020-002141-42 |
PelvEx II | P3 |
Active, not recruiting |
Colorectal Cancer |
2028-07-03 |
2022-03-13 |
Treatments |
|
NCT03803553 |
NCT03803553 | P3 |
Recruiting |
Colorectal Cancer |
2026-12-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
2022-501181-22-01 |
STEREOPAC-001 | P2 |
Recruiting |
Adenocarcinoma|Pancreatic Cancer |
2032-10-01 |
2025-05-02 |
Treatments |
|
2023-509814-12-00 |
2023-509814-12-00 | P2 |
Recruiting |
Colorectal Cancer |
2031-03-31 |
2025-05-02 |
||
2024-513008-32-00 |
M24-977 | P2 |
Not yet recruiting |
Gastrointestinal Cancer|Esophageal Cancer|Adenocarcinoma |
2030-11-03 |
2025-05-02 |
Treatments |
|
NCT06628310 |
AndroMETa-GEA | P2 |
Recruiting |
Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer |
2030-10-01 |
12% |
2024-12-19 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
2020-003134-20 |
MEND-IT | P2 |
Active, not recruiting |
Colorectal Cancer |
2030-05-17 |
2022-03-13 |
Treatments |
|
NCT07290985 |
AACR-ADOPT-GEA | P2 |
Not yet recruiting |
Adenocarcinoma|Gastrointestinal Cancer|Esophageal Cancer |
2028-06-01 |
12% |
2025-12-19 |
Primary Endpoints|Treatments |
2024-518469-84-00 |
ââD798VC00001â | P2 |
Not yet recruiting |
Colorectal Cancer |
2028-01-20 |
|||
2024-518841-12-00 |
NeoART | P2 |
Recruiting |
Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer |
2027-12-31 |
12% |
2025-05-02 |
Treatments |
NCT06835387 |
HCRN GI23-617 | P2 |
Recruiting |
Adenocarcinoma |
2027-08-01 |
2% |
2025-04-04 |
Primary Endpoints|Start Date|Treatments|Trial Status |